Ovarian Cancer Research
Studies are Looking for
While Lynparza is a huge step for the hereditary cancer community, more work needs to be done. If you are interested in participating in a clinical trial, please visit the research section of the FORCE website to find a trial that is recruiting in your area. Some of the featured studies you can learn about include:
- QUADRA is a study for women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian
tube, or primary peritoneal cancer who have received at least three previous chemotherapy regimens (which may have included a PARP inhibitor).
- ARIEL2 is a Phase 2 PARP inhibitor trial for women with relapsed, high-grade serous or endometrioid ovarian cancer. ARIEL2 is now enrolling its expansion phase to include patients who have failed three lines of prior chemotherapy and are platinum sensitive or platinum resistant. All patients enrolled in the study will receive the PARP inhibitor rucaparib.
- The Consortium for Long-Term Survival, led by the Mass General Cancer Center and funded by the Department of Defense, is a research group seeking long-term survivors of ovarian cancer. If you are a survivor of eight years or more of stage III or stage IV ovarian cancer, your participation can help to improve the treatment, survival, and survivorship of all women. Contact Giulia Fulci, firstname.lastname@example.org if you are interested in participating.
We welcome your feedback. Please send your comments to Sue
fill out our Newsletter